MedTrace Logo

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

NCT00762255 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2013-07-25

No results posted yet for this study

Summary

The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.

Conditions

Interventions

DRUG

Vorinostat

Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

DRUG

Bevacizumab

Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

DRUG

Irinotecan

Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Sponsors & Collaborators

Principal Investigators

  • Prakash Chinnaiyan, M.D. · H. Lee Moffitt Cancer Center & Research Institute, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762255 on ClinicalTrials.gov